Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in.
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients.
StockNews.com assumed coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock. Shares of ADXS opened at $0.10 on Monday. Advaxis has a one year low of $0.08 and a one year high of $0.76. The company has a […]
StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note released on Tuesday morning. The firm issued a sell rating on the stock. Shares of Advaxis stock opened at $0.10 on Tuesday. The stock has a market capitalization of $14.53 million, a PE ratio of -1.00 and a beta of […]
StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock. ADXS opened at $0.10 on Tuesday. The company has a market cap of $15.22 million, a PE ratio of -1.05 and a beta of 2.11. Advaxis […]